Previous Article | Next Article 
Journal of Clinical Microbiology, September 2000, p. 3150-3155, Vol. 38, No. 9
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Role of IS6110-Targeted PCR, Culture, Biochemical,
Clinical, and Immunological Criteria for Diagnosis of Tuberculous
Meningitis
M.
Caws,1,*
S. M.
Wilson,1
C.
Clough,2 and
F.
Drobniewski1
PHLS Mycobacterium Reference Unit, Dulwich
PHL and Department of Microbiology, Guy's King's and St. Thomas
School of Medicine, King's College (Dulwich), London SE22
8QF,1 and Department of Neurology,
King's College Hospital, London SE5,2 United
Kingdom
Received 6 March 2000/Returned for modification 11 May
2000/Accepted 13 June 2000
 |
ABSTRACT |
An open prospective clinical, microbiological, and molecular
analysis of a national molecular diagnostic service for tuberculous meningitis (TBM) using an in-house IS6110-targeted PCR for
molecular "Fastrack" diagnosis was carried out. Between April 1997 and June 1998. Consecutive cerebrospinal fluid (CSF) samples from 131 patients were assessed. Against a culture on the same sample, PCR had a sensitivity of 75% and a specificity of 94%. Of samples from patients classified as definite or probable TBM cases based on clinical criteria, 81% had raised CSF protein levels and 73% had a
lymphocytosis, although 57% of all submitted samples showed a raised
lymphocyte count. While only 46% had a CSF glucose level below the
normal range, the CSF glucose level was significantly lower
(P = 0.0281) than in cases of meningitis of other
etiologies. Levels of tumor necrosis factor alpha were also found to be
significantly raised in definite or probable TBM cases
(P = 0.028), while adenosine deaminase levels were
not. The study showed IS6110-targeted PCR to be a rapid,
sensitive, and specific test in routine use for the diagnosis of TBM.
 |
INTRODUCTION |
Due to inconsistent clinical
presentations, rarity (106 notifications in England and Wales, 1996 [17]), and the lack of a rapid, sensitive,
and specific test, tuberculous meningitis (TBM) is particularly
difficult to diagnose (27). While conventional microscopy
and culture are widely used, smear microscopy is insensitive (usually
10 to 20%, although sometimes higher, especially when multiple samples
or large volumes are processed) (5), and culture takes up to
4 to 6 weeks to provide a result, limiting the value of these methods
in aiding diagnosis and immediate decisions on treatment. Any delays in
initiating the correct drug regime lead to increased
neurological sequelae and mortality rates, and so diagnosis is made
on assessment of clinical presentation, cerebrospinal fluid (CSF)
biochemistry, microscopy, and evidence of current or prior tuberculosis
(TB) (7). However, presentations are diverse and rarely fit
a "classical picture" of TBM symptoms. At present, the culture
method provides a retrospective "gold standard" diagnosis and
rapid, sensitive, and specific tests are urgently needed to aid the
clinician. Many tests have been advocated for the diagnosis of TBM,
including the bromide partition test (11, 26, 29), the
adenosine deaminase assay (14, 18, 31) and, more recently,
latex particle agglutination (9), high-pressure liquid
chromatography (3), and various PCR (2, 12, 16, 20, 25,
30)- and enzyme-linked immunosorbent assay (ELISA) (1, 13,
15)-based tests. While immunodiagnostic techniques may show
promise, at present they lack sufficient sensitivity and often the
necessary specificity. PCR is the most widely applied alternative rapid
diagnostic technique for TBM. The present study was an open prospective
analysis of samples referred to the Public Health Laboratory Service
Mycobacterium Reference Unit (PHLS MRU) for England and Wales for
testing under a national "Fastrack" PCR diagnostic service for TBM
between April 1997 and June 1998. A nested-PCR assay was chosen to
maximize sensitivity since volumes of CSF available for TBM PCR
are often lower than requested. Stringent precautions were taken
against contamination, namely, there were three separate dedicated
rooms for preparation of master mixes (clean area), extraction of DNA
and addition of sample (gray area), and amplification and detection of
sample (dirty area). Negative controls and inhibition controls were
included with each run. Assessments of sensitivity and specificity were
made using both culture as a gold standard and assessment of clinical
data and treatment. While PCR has been shown to be more sensitive than culture in several studies, problems with contamination and
therefore specificity make it unsuitable as a gold standard until
methods and especially controls are standardized across laboratories. A
total of 131 samples from 131 patients were assessed during the study
period using an in-house PCR assay based on detection of the
IS6110 insertion sequence, which was a modification of the
method of Wilson et al. (30).
 |
MATERIALS AND METHODS |
A national Fastrack PCR diagnostic service was offered for CSF
samples referred to the PHLS MRU for TBM testing. Guidance on CSF
volumes was provided, with a recommended volume of 1 ml or greater and
a minimum volume of 0.5 ml. Where this service was requested, samples
were processed as outlined below. Clinical data were sought
prospectively in all cases and retrospectively by follow-up
questionnaire. The following parameters were requested: name, age,
gender, presence of fever, meningism, photophobia, immunocompromised
status, computed tomography and magnetic resonance imaging (MRI) scan
results, TB contact and history, CSF biochemistry (protein, glucose,
white cell count, and lymphocyte count), blood glucose level,
microscopy, and the results of other investigations for viral-bacterial
infections. Data were also sought retrospectively on the final
diagnosis, treatment given, and outcome. Where there was sufficient
volume, sample supernatants were also analyzed for adenosine deaminase
levels, tumor necrosis factor alpha (TNF-
) levels and, using PCR,
for herpes simplex virus (HSV) types 1 and 2 and varicella-zoster virus
(VZV) according to established methods (6, 19).
For further analysis patients were classified as definite TBM cases
when a positive culture was obtained and as probable TBM cases through
assessment of CSF biochemistry, clinical presentation, radiological
findings, medical history, treatment, progression, and the clinician's
final diagnosis. Between April 1997 and June 1998 131 samples were tested.
Sample processing.
When a >1-ml CSF sample was received,
the excess CSF was inoculated directly into an MB BacT culture vial
(Organon Teknika, Cambridge, United Kingdom) and onto a
Lowenstein-Jensen slope. In cases where a <1-ml CSF sample was
received, all of the sample was removed for PCR, and in all cases the
sample container was rinsed with Kirchner medium and cultured.
DNA extraction.
DNA was extracted according to the
chloroform extraction method of Wilson et al. (30). One
milliliter of CSF (or the available volume, with a minimum of 0.5 ml)
was centrifuged at 12,000 × g for 15 min. The
supernatant was removed and stored at
20°C. The pellet was washed
with 1 ml distilled water. Then, 25 µl of distilled water and an
equal volume of chloroform was added to the tube. The pellet was
resuspended and dispersed by vigorous mixing, followed by incubation in
a water bath at 80°C for 20 min. Samples were removed from the water
bath and cooled in a freezer for several minutes before being brought
back to room temperature and briefly centrifuged to ensure clear
separation of the aqueous phase.
IS6110 PCR.
Ten microliters of the aqueous phase
was added to the PCR reaction to give a final reaction volume of 40 µl. A 9-µl portion of each extract was also added to a second
identical reaction, along with 1 µl of a 500-fg/µl mixture of DNA
extracted from BCG (ca. 100 genome equivalents) to serve as an
inhibition control. One milliliter of distilled water was processed in
parallel with each CSF sample as a negative control, with a minimum of
four negative controls per run. A high (500 fg/reaction, 100 genome equivalents) and a low (50 fg/reaction, 10 genome equivalents) positive
control of BCG DNA extract were included with each PCR run.
A nested PCR was performed using 0.2-ml thinwall Apex tubes (Alpha,
Eastleigh, United Kingdom). Reactions included final concentrations of
16 mM (NH4)SO4 reaction buffer (Bioline,
London, United Kingdom); 200 µM concentrations of dATP, dCTP, and
dGTP; 100 µM concentrations of dUTP and dTTP (Pharmacia Biotech); 1.5 mM MgCl2; 0.23 mg of bovine serum albumin per ml; 5%
(vol/vol) dimethyl sulfoxide; and 20 pmol of primers and 1 U of
Taq (Bioline) per reaction. Volumes were made up with
distilled water. A 1-µl first-round product was added to 20 µl of
the inner reaction mix for the nested reaction. The outer reaction
cycle consisted of 2 min at 93°C, followed by 30 cycles of 20 s
at 93°C, 30 s at 65°C, and 1 min at 72°C, with a final hold
step of 10 min at 72°C. The inner reaction cycle was identical except
for an annealing temperature of 48°C, a reaction volume of 20 µl,
and 0.5 U of Taq polymerase per reaction. The outer primers
were TB294 (5'-GGACAACGCCGAATTGCGAAGGGC-3') and TB850
(5'-TAGGCGTCGGTGACAAAGGCCACG-3'). The inner primers were
TB505 (5'-ACGACCACATCAACC-3') and TB670
(5'-AGTTTGGTCATCAGCC-3'). PCR was performed in a
Perkin-Elmer (Langen, Germany) 9600 Thermocycler. After amplification,
the product was visualized by electrophoresis on 2% agarose gel by
ethidium bromide staining.
Viral PCR.
PCR for HSV types 1 and 2 and VZV was carried out
on 73 samples for which sufficient CSF supernatant remained according
to the method of Read et al. (19) and Jeffery et al.
(6). Reagent sources were the same as for the
IS6110 PCR.
Adenosine deaminase assay.
Adenosine deaminase levels were
determined by the colorimetric assay of Giusti (4). An
adenosine deaminase-positive control (50 U/liter) was incubated in
parallel with the samples in each run. All solutions were prepared
using AnalaR water (Merck, Lutterworth, United Kingdom) to minimize
background values from ammonium in the water. The formation of blue
indophenol was measured at 628 nm with a Genesys 5 spectrophotometer
(Life Sciences International, Runcorn, United Kingdom) against a
distilled-water blank. All other reagents were from Sigma-Aldrich,
Dorset, United Kingdom.
TNF-
assay.
TNF-
assays were performed using sandwich
human TNF-
ELISA kits from Genzyme (Cambridge, United Kingdom)
according to the manufacturer's instructions. Data were analyzed, and
unknowns were determined from standard curves using Graphpad PRISM
software (Intuitive Software for Science, San Diego, Calif.).
CSF spiking experiments.
Assays were performed in which CSF
samples from patients not suspected of TBM were spiked with
Mycobacterium tuberculosis or BCG to demonstrate the
sensitivity of the IS6110 PCR test in CSF. Pooled CSF was
spiked with IS6110 high-copy-number (17 copies) and
low-copy-number (1 copy) M. tuberculosis strains. CSF was also spiked with BCG (one IS6110 copy). Unspiked CSF,
distilled water, inhibition controls, and high (500 fg/reaction, 100 genome equivalents) and low (50 fg/reaction, 10 genome equivalents)
positive controls (as previously) were included with each run. To
minimize clumping of bacteria, cultures were vortexed for 10 s,
sonicated for 10 s, revortexed for a further 10 s, and left
to stand for 5 min to allow any remaining large clumps to settle. A
total of 900 µl of CSF sample was spiked with 100 µl of each
culture dilution in triplicate. Colony counts were established from the
same dilution series to enumerate the bacteria present. CSF was then
processed as for the clinical samples, as outlined above, except that
the extractions were made into 50 µl of distilled water plus 50 µl of chloroform in cases where a 25 µl-25 µl volume would be used for clinical samples. Since there was insufficient CSF available, experiments were repeated, spiking distilled water, in place of CSF, to
allow 20 replicates to be performed at the minimum CFU count.
 |
RESULTS |
IS6110 sensitivity.
The IS6110 PCR
detected M. tuberculosis in CSF with a high sensitivity
(Table 1). IS6110-targeted PCR
showed an increase in sensitivity, detecting the M. tuberculosis strain with 17 IS6110 target copies
compared to both BCG (one IS6110 copy) and the M. tuberculosis strain with 1 IS6110 copy using spiked
preparations in distilled water. (P = 0.0248, Fisher's
exact test) (Table 2).
CSF analysis.
A total of 131 samples from different patients
were assessed by IS6110 PCR during the study period (Table
3). Of these, 23 (17.5%) were found to
be positive by culture or PCR or were classified as probable TBM cases
through assessment of CSF biochemistry, clinical presentation,
radiological findings, medical history, treatment, progression, and the
clinician's final diagnosis. Data for these cases are presented in
Table 4, along with the results for the
sample which tested positive by PCR but which was determined to be a
false positive. However, only four samples processed for PCR were
culture positive, although in five cases a positive culture was
obtained within 3 months from subsequent samples not processed by PCR
in cases where the original sample was both PCR and culture negative,
one of which was a brain biopsy. In 15 cases no culture result was
available.
Using culture on the same sample as the gold standard of diagnosis, the
IS
6110 PCR test had a sensitivity of 75% and a specificity
of 94%. Of 112 culture-negative patients, 13 were classified as
probable cases of TBM (see Table
4 for principal findings and
notes),
and 5 of these were detected by PCR. One sample which
was PCR positive
yet culture negative was determined to be a false
PCR positive by an
examination of the clinical history, treatment,
and progression.
Attempts were made to follow up the specimen
which was culture positive
and PCR negative as outlined previously.
No sample was available for
repeat testing, no response was obtained
to questionnaires, and no
subsequent specimens were received at
the reference center. A summary
of the principal clinical findings
in definite and/or probable TBM
cases is given in Table
4.
The gender distribution of submitted samples was equal, with 56%
(
n = 73) and 44% (
n = 58) from male
and female patients,
respectively. Of those classified as definite or
probable cases
of TBM 69.5% (
n = 16) were male, while
30% (
n = 7) were female.
The ages (in years) of 116 (96%) patients were known: 22 (18%)
patients were under age 20, 54 (45%) patients were between age
21 and age 50, and 40 (33%) patients
were age 50 or older; the
age of 5 (4%) patients was not known. The
age distribution was
similar among positive patients: 24%, (5 patients), 0 to 20 years
43% (10 patients), 21 to 50 years; and 35%
(8 patients), 50 years
or older. Nine percent of patients were known to
be human immunodeficiency
virus (HIV) positive; three (13%) of the
patients with definite
or probable TBM were HIV
positive.
Only 20% (15 of 75) of submitted samples with CSF biochemistry data
available fit the classic "raised-protein, low-glucose"
profile
(Fig.
1), although 61% (46 of 75) had
raised protein levels
with normal or raised glucose. Therefore, only
19% (14 of 75)
had normal or low protein levels. Of patients
classified as definite
or probable TBM cases, CSF biochemistry results
were available
for 17. Interestingly, only 8 of the 17 (47%) fit the
classic
raised-protein, low-glucose picture (see Fig.
1), while 6 (35%)
had a raised protein level but normal glucose and 2 (12%) had
normal values for both protein and glucose. Of 61 samples, 35
(57%)
had raised lymphocyte levels with 8 of 11 (73%) definite
or probable
TBM cases having raised lymphocyte levels. This was
expected, since
lymphocytosis would be a key factor in referral
for TBM testing;
however, a raised lymphocyte count could not
be used to differentiate
between TBM and meningitis of other etiologies
in this study
(
P = 0.494, Table
3). Of those 23 finally considered
definite (culture positive or PCR positive with full treatment
and
final clinical diagnosis of TBM) or probable TBM cases, culture
on a
single sample had a sensitivity of only 17%, which rose to
39% when
multiple samples were processed, while PCR showed a sensitivity
of
35%.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 1.
CSF protein versus glucose for all samples. Normal
values were as follows: glucose, 2.5 to 5.5 mmol/liter; protein, 0.15 to 0.4 g/liter. Symbols: ×, definite and probable TBM cases; , all
other samples.
|
|
Where additional information was available, the numbers of diagnoses of
negative patients were as follows: viral, 10; bacterial,
6; trauma, 3;
Wegener's granulomatosis, 1; cerebral vasculitis,
2; cancer, 4;
Still's disease, 2; multiple sclerosis, 1; idiopathic
chronic parchymeningitis, 1; polyradiculopathy, 1; pituitary
mass,
1; thyroid storm, 1; retinitis, 1; infective endocarditis, 1;
spastic paraplegia, 1; spontaneous recovery, 1; uncertain final
diagnosis, 13; lost to follow-up, 3; no response to questionnaire,
57. Of the viral cases, three were HSV (two were independently
confirmed in
this study), one was VZV (also independently confirmed),
one was
cytomegalovirus, one was JC virus (JCV), and four were
unspecified.
Twenty-nine cases for whom there was no response
to the questionnaire
had negative results for both HSV and VZV
by
PCR.
Viral PCR.
Sufficient CSF was available for HSV and VZV
testing by PCR for 73 of the samples, including 29 of the samples for
which no response to the retrospective questionnaire was obtained: 70 samples were negative for both viruses, 2 samples were positive for
HSV, and one sample was positive for VZV. In all cases, positive and negative PCR controls performed correctly.
Mann-Whitney analysis.
Glucose was found to be significantly
lower in TBM cases than in meningitis cases of other etiologies
(P = 0.0317). TNF-
levels were significantly higher
(P = 0.037). No value is given for the adenosine
deaminase and TNF-
values of culture-positive TBM cases versus
negative or viral cases since the number of culture-positive cases
where sufficient CSF remained for these tests was too small (Table
5).
 |
DISCUSSION |
The CSF PCR for TBM, while less sensitive than the culture method,
when culture is used as the gold standard, is rapid and therefore of
value when the clinical suspicion is high and the results are reviewed
in parallel with clinical and other laboratory findings. It is more
sensitive than conventional smear microscopy, which detects 10 to 20%
of cases, and other available rapid techniques. During follow-up, it
became evident that many samples were inappropriately referred to the
MRU for TBM testing as part of general screening where there was little
or no clinical suspicion of TBM. Due to the rarity of the disease, the
fact that a negative result cannot exclude a diagnosis of TBM, the high
cost of testing, and the comparatively large volume of fluid required,
CSF PCR should not be used as a "screening" procedure, particularly
where suspicion of an alternative viral or bacterial diagnosis is high.
It is difficult to judge the sensitivity of any test for TBM in the absence of a reliable gold standard, and so a negative result cannot be
used to exclude a diagnosis of TBM. This test should only be performed
where the index of suspicion for TBM is high, and treatment should not
be withheld on the basis of a PCR result alone. In addition, many
samples referred to the MRU during the test period were below the
requested volume of 1 ml, which, while unavoidable in neonates and
young children, compromises the value of negative test results. PCR
methodology can add to the overall decision-making process when
considered in tandem with the results of microscopy, evidence of TB
contact, clinical evidence of TB elsewhere, CSF biochemistry, and
radiology. It is useful when combined antibacterial, TB, and antiviral
therapy is initiated in cases of severe meningitis with subsequent
clinical improvement, but the reason for the therapeutic improvement
remains unclear. In these cases the decision to discontinue TB therapy
if no other infectious cause is identified can be supported by negative
PCR results and continuing negative culture.
A recent paper by Kumar et al. (10) found five
clinical and/or laboratory features to be independently associated with
the diagnosis of TBM: a prodomal stage of >7 days, fundal optic
atrophy, focal deficit, extrapyramidal movements, and a CSF leukocyte
level of <50% polymorphs. The presence of three or more of these
features had a specificity of 98.4% but a sensitivity of only 54.5%.
In this study the CSF glucose was lower in TBM cases than in patients with meningitis of other etiologies (P = 0.0281)
although, contrary to expectations, not usually outside a normal range
of 2.5 to 5.5 mmol/liter (mean for TBM cases, 2.813 mmol/liter). Undue
emphasis should not be placed on the expectation of low glucose values in TBM when assessing the biochemical findings, while a raised protein
concentration is a useful indicator but cannot exclude meningitis of
other etiologies (P = 0.5608). The CSF glucose level should always be assessed in parallel with the blood glucose level, and
apparently this was rarely done, or not recorded, which reduces the
utility of a CSF glucose value in differential diagnosis.
TNF-
was also significantly raised in TBM cases (P = 0.028, Table 5). However, since there is overlap between TBM cases and negative CSF values (Fig. 2), this
test is of limited use in isolation. No significant difference was
found in adenosine deaminase levels, although other studies have found
a cutoff value of 9 to 10 U/liter giving sensitivities of 100%, with
specificities of 87.6 to 99% (21, 22, 24).
An earlier study by Scarpellini et al. (23) had indicated
that the detection limits for an IS6110-based PCR assay
using spiked bacterial suspensions was 50 CFU/ml. The sensitivity of the assay in this study was comparable to those described earlier (8, 28).
It is clear that PCR is currently the most rapid diagnostic test
for TBM that provides an acceptable sensitivity in comparison to the
culture method. However, it requires a relatively large volume of CSF
(a particular problem in young children, who are more susceptible to
TBM), several dedicated but separate laboratory areas, and rigorous
quality control to guard against contamination and to maintain
sensitivity and specificity. Thus, results should always be reviewed in
parallel with clinical findings.
 |
ACKNOWLEDGMENTS |
We thank Malcolm Yates and the staff of the MRU for their work on
this study, Richard Hooper for his help with the statistical analysis,
and all of the clinicians, microbiologists, and laboratory staff at
participating centers.
This work was supported by a grant from JRC, KCSMD, and the PHLS.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: PHLS
Mycobacterium Reference Unit, Dulwich PHL and Department of
Microbiology, Guy's King's and St. Thomas School of Medicine, Kings
College (Dulwich), East Dulwich Grove, London SE22 8QF, United Kingdom.
Phone: 0208-693-1312. Fax: 0207-346-6477. E-mail:
maxine.caws{at}kcl.ac.uk.
 |
REFERENCES |
| 1.
|
Baig, S. M.
1995.
Anti-purified protein derivative cell-enzyme-linked immunosorbent assay, a sensitive method for early diagnosis of tuberculosis meningitis.
J. Clin. Microbiol.
33:304-341[Abstract].
|
| 2.
|
Bonington, A.,
J. I. George-Strang,
P. E. Klapper,
S. V. Hood,
W. Rubombora,
M. Penny,
R. Willers, and E. G. A. Wilkins.
1998.
Use of Roche amplicor in early diagnosis of tuberculosis meningitis.
J. Clin. Microbiol.
36:1251-1254[Abstract/Free Full Text].
|
| 3.
|
Brooks, J. B.,
V. Syriopoulou,
W. R. Butler,
G. Saroglow,
K. Karydis, and P. L. Almenoff.
1998.
Development of a quantitative chemical ionization gas chromatography mass spectrometry method to detect tuberculostearic acid in body fluids.
J. Chromatogr. B
712:1-10.
|
| 4.
|
Giusti, G.
1974.
Methods in enzymatic analysis: adenosine deaminase, 2nd ed., p. 1092-1099.
Verlag-Chemie, Wiechen, Germany.
|
| 5.
|
Hopewell, P. C.
1994.
Overview of clinical tuberculosis: tuberculosis, pathogenesis, protection, and control.
ASM Press, Washington, D.C.
|
| 6.
|
Jeffery, K. J. M.,
S. J. Reda,
T. E. A. Peto,
R. T. Mayon-White, and C. R. M. Bangham.
1997.
Diagnosis of viral infections of the central nervous system: clinical interpretation of PCR results.
Lancet
349:313-317[CrossRef][Medline].
|
| 7.
|
Kennedy, D. H., and R. J. Fallon.
1979.
Tuberculosis meningitis.
JAMA
241:264-268[Abstract/Free Full Text].
|
| 8.
|
Kolk, A. H. J.,
A. R. J. Schuitema,
S. Kuijper,
J. van Leeuwen,
P. W. M. Hermans,
J. D. A. van Embden, and R. A. Hartskeer.
1992.
Detection of Mycobacterium tuberculosis in clinical samples by using polymerase chain reaction and a nonradioactive detection system.
J. Clin. Microbiol.
30:2567-2575[Abstract/Free Full Text].
|
| 9.
|
Krambovitis, E.,
M. B. McIllmurray,
P. E. Lock,
W. Hendrickse, and H. Hovel.
1984.
Rapid diagnosis of tuberculosis meningitis by latex particle agglutination.
Lancet
ii:1229-1231[CrossRef].
|
| 10.
|
Kumar, R.,
S. N. Singh, and N. Kohli.
1999.
A diagnostic rule for tuberculosis meningitis.
Arch. Dis. Child.
81:221-224[Abstract/Free Full Text].
|
| 11.
|
Mandal, B. K.,
D. I. K. Evans,
A. G. Ironside, and B. R. Pullan.
1972.
Radioactive bromide partition test in differential diagnosis of tuberculosis meningitis.
Br. Med. J.
4:413-415.
|
| 12.
|
Mazurek, G. H.,
V. Reddy,
D. Murphy, and T. Ansari.
1996.
Detection of mycobacterium tuberculosis in CSF following immunomagnetic enrichment.
J. Clin. Microbiol.
34:450-453[Abstract].
|
| 13.
|
Miörner, H.,
U. Sjöbring,
P. Nayak, and A. Chandramuki.
1995.
Diagnosis of tuberculosis meningitis: comparison of three immunoassays, an immune complex assay and the PCR.
Tubercle Lung Dis.
76:381-386[CrossRef][Medline].
|
| 14.
|
Mishra, O. P.,
G. Nath,
V. Loiwal,
Z. Ali,
L. Chandra, and B. K. Das.
1995.
CSF Adenosine deaminase activity and C-reactive protein in tuberculosis and partially treated bacterial meningitis.
Indian Pediatr.
32:886-889[Medline].
|
| 15.
|
Park, S. C.,
B. L. Lee,
S. N. Cho,
W. J. Kim, and B. C. Lee.
1993.
Diagnosis of tuberculsis meningitis by detection of IgG antibodies to purified protein derivative and LAM Antigen in CSF.
Tubercle Lung Dis.
74:317-322[CrossRef][Medline].
|
| 16.
|
Pfyffer, G. E.,
P. Kissling,
E. M. I. Jahn,
H. Welscher,
M. Salfinger, and R. Weber.
1996.
Diagnostic performance of amplified MTB direct test with CSF and other respiratory and nonrespiratory specimens.
J. Clin. Microbiol.
34:834-841[Abstract].
|
| 17.
|
Public Health Laboratory Service, Communicable Disease Surveillance Center.
1998.
Communicable disease statistics, 1998, England and Wales.
Public Health Laboratory Service, CDSC, London, United Kingdom.
|
| 18.
|
Prasad, R.,
A. Kumar,
B. K. Khanna,
P. K. Mukerji,
S. K. Agarwai,
A. Kumar, and V. M. L. Srivastava.
1991.
Adenosine deaminase activity in CSF for diagnosis of tuberculosis meningitis.
Indian J. Tuberculosis
38:99-102.
|
| 19.
|
Read, S. J.,
K. J. M. Jeffery, and C. R. M. Bangham.
1997.
Aseptic meningitis and encephalitis: the role of PCR in the diagnostic laboratory.
J. Clin. Microbiol.
35:691-696[Abstract].
|
| 20.
|
Reischl, U.,
N. Lehn,
H. Wolf, and L. Nauman.
1998.
Clinical evaluation of the automated COBAS AMPLICOR MTB assay for testing respiratory and nonrespiratory specimens.
J. Clin. Microbiol.
36:2853-2860[Abstract/Free Full Text].
|
| 21.
|
Ribera, E.,
J. M. Martinez-Vazquez,
I. Ocaña,
R. M. Segura, and C. Pascual.
1987.
Activity of adenosine deaminase in CSF for diagnosis and follow-up of tuberculosis meningitis in adults.
J. Infect. Dis.
155:603-607[Medline].
|
| 22.
|
Rohani, M. Y.,
Y. M. Cheong, and J. M. Rani.
1995.
The use of adenosine deaminase activity as a biochemical marker for the diagnosis of tuberculosis meningitis.
Malays. J. Pathol.
17:67-71[Medline].
|
| 23.
|
Scarpellini, P.,
S. Braglia,
A. M. Brambilla,
M. Dalessandro,
P. Chichero,
A. Gori, and A. Lazzarin.
1997.
Detection of rifampicin resistance by single-strand conformation polymorphism analysis of cerebrospinal fluid of patients with tuberculosis of the central nervous system.
J. Clin. Microbiol.
35:2802-2806[Abstract].
|
| 24.
|
Segura, R. M.,
C. Pascual,
I. Ocaña,
J. M. Martinez-Vazquez,
E. Ribera,
I. Ruiz, and M. D. Pelegri.
1989.
Adenosine deaminase in body fluids: a useful diagnostic tool in tuberculosis.
Clin. Biochem.
22:141-148[CrossRef][Medline].
|
| 25.
|
Seth, P.,
G. K. Ahuja,
N. Vijaya Bhanu,
M. Behari,
S. Bhowmik,
S. Broor,
L. Dar, and M. Chakraborty.
1996.
Evaluation of PCR for rapid diagnosis of clinically suspected tuberculosis meningitis.
Tubercle Lung Dis.
77:293-388[CrossRef][Medline].
|
| 26.
|
Taylor, L. M.,
H. V. Smith, and G. Hunter.
1954.
The blood-CSF barrier to bromide in diagnosis of tuberculosis meningitis.
Lancet
i:700-702[CrossRef].
|
| 27.
|
Weatherall, D. J.,
J. G. G. Leddingham, and D. A. Warrell.
1996.
Oxford textbook of medicine, 3rd ed.
Oxford University Press, Oxford, United Kingdom.
|
| 28.
|
Whelen, A. C.,
T. A. Felmlee,
J. M. Hunt,
D. L. Williams,
G. L. Roberts,
L. Stockman, and D. H. Persing.
1995.
Direct genotypic detection of Mycobacterium tuberculosis rifampicin resistance in clinical specimens by using single-tube heminested PCR.
J. Clin. Microbiol.
33:556-561[Abstract].
|
| 29.
|
Wiggelinkhuizer, J., and M. Mann.
1980.
The radioactive bromide partition test in the diagnosis of tuberculosis meningitis in children.
J. Pediatr.
97:843-847[CrossRef][Medline].
|
| 30.
|
Wilson, S. M.,
R. McNerney,
P. M. Nye,
G. Godfrey-Faussett,
N. G. Stoker, and A. Voller.
1993.
Progress towards a simplified polymerase chain reaction and its application to diagnosis of tuberculosis.
J. Clin. Microbiol.
31:776-782[Abstract/Free Full Text].
|
| 31.
|
Yu, S. Z.,
S. X. Zhao, and Y. Dai.
1993.
The activities of three enzymes in serum and cerebrospinal fluid for diagnosis of tuberculosis meningitis.
Chin. J. Tuberc. Respir. Med.
16:39-40.
|
Journal of Clinical Microbiology, September 2000, p. 3150-3155, Vol. 38, No. 9
0095-1137/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Baveja, C P, Gumma, V., Jain, M., Choudhary, M., Talukdar, B, Sharma, V K
(2009). Newer methods over the conventional diagnostic tests for tuberculous meningitis: do they really help?. Trop Doct
39: 18-20
[Abstract]
[Full Text]
-
Rock, R. B., Olin, M., Baker, C. A., Molitor, T. W., Peterson, P. K.
(2008). Central Nervous System Tuberculosis: Pathogenesis and Clinical Aspects. Clin. Microbiol. Rev.
21: 243-261
[Abstract]
[Full Text]
-
Kulkarni, S P, Jaleel, M A, Kadival, G V
(2005). Evaluation of an in-house-developed PCR for the diagnosis of tuberculous meningitis in Indian children. J Med Microbiol
54: 369-373
[Abstract]
[Full Text]
-
Cloud, J. L., Shutt, C., Aldous, W., Woods, G.
(2004). Evaluation of a Modified Gen-Probe Amplified Direct Test for Detection of Mycobacterium tuberculosis Complex Organisms in Cerebrospinal Fluid. J. Clin. Microbiol.
42: 5341-5344
[Abstract]
[Full Text]
-
DeBiasi, R. L., Tyler, K. L.
(2004). Molecular Methods for Diagnosis of Viral Encephalitis. Clin. Microbiol. Rev.
17: 903-925
[Abstract]
[Full Text]
-
Johansen, I. S., Lundgren, B., Tabak, F., Petrini, B., Hosoglu, S., Saltoglu, N., Thomsen, V. O.
(2004). Improved Sensitivity of Nucleic Acid Amplification for Rapid Diagnosis of Tuberculous Meningitis. J. Clin. Microbiol.
42: 3036-3040
[Abstract]
[Full Text]